Research programme: heparosan-based conjugates - Caisson Biotech/Novo Nordisk

Drug Profile

Research programme: heparosan-based conjugates - Caisson Biotech/Novo Nordisk

Latest Information Update: 29 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Caisson Biotech; Novo Nordisk
  • Class Amino sugars; Drug conjugates; Glucuronic acids; Insulins; Pancreatic hormones; Polysaccharides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus
  • Research Haemophilia

Most Recent Events

  • 24 Aug 2016 Caisson Biotech has patent protection for Factor VIIa HEPtune® Conjugate in USA
  • 24 Aug 2016 Pharmacodynamics data from research studies in Haemophilia released by Caisson Biotech
  • 11 Mar 2014 Preclinical trials in Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top